School of Medicine
Medical tablets, capsules and caplets flying out of a bottle against a light blue background

People

Image of Emma O'Dowd

Emma O'Dowd

Clinical Associate Professor in Respiratory Medicine, Faculty of Medicine & Health Sciences

Contact

  • workRoom B21 Clinical Sciences Building
    Nottingham City Hospital
    Hucknall Road
    Nottingham
    NG5 1PB
    UK

Biography

Dr Emma O'Dowd is an honorary consultant respiratory physician at Nottingham University Hospitals NHS Trust and associate clinical professor in respiratory medicine at University of Nottingham. She was awarded a PhD entitled Factors influencing the diagnosis and subsequent prognosis in patients with lung cancer in April 2017 funded by the Roy Castle Lung Cancer Foundation. Her research interests are lung cancer screening and early diagnosis of lung cancer. She is chair of the British Thoracic Society Lung Cancer & Mesothelioma Advisory Group, member of the Lung Cancer Clinical Expert Group and the IASLC Tobacco Control and Smoking Cessation Committee.

Expertise Summary

Lung cancer screening.

Interventional procedures.

Research Summary

SELECT Selection of Eligible People for Lung Cancer Screening using Electronic Primary Care DaTa: Development of new risk prediction models. £358,737. Cancer Research UK. 2018-2024.… read more

Recent Publications

Current Research

  1. SELECT Selection of Eligible People for Lung Cancer Screening using Electronic Primary Care DaTa: Development of new risk prediction models. £358,737. Cancer Research UK. 2018-2024. Co-applicant
  2. 4-IN-THE-LUNG-RUN Towards INdividually tailored INvitations, screening INtervals, and INtegrated co-morbidity reducing strategies in lung cancer screening): A Randomised Comparison of Personalised Lung Cancer Screening Regimens. €7,999,787. Horizon 20:20. 2020-2024. Co-applicant (€400,000 to Nottingham)
  3. DECLINE: DEcisions against Curative treatment for Lung cancer IN Eligible patients. £210,810. Roy Castle Lung Cancer Foundation. 2020-2024. Principal applicant
  4. Use of virtual reality to deliver prehabilitation in patients undergoing lung cancer surgery. £144,000. NHSX. 2022-2024. Co-Principal applicant
  5. Determining the impact of CT analysis software on lung nodule diagnosis (DOLCE). £1,479,044. NHSX AI. 2022-2025. Co-applicant
  6. Phase IV AI. Horizon Europe/ UKRI. Euro 7998990. (Euro 389363 to NUH). Co-applicant. 2023- 2026.

School of Medicine

University of Nottingham
Medical School
Nottingham, NG7 2UH

Contacts: Call 0115 823 0031 ext.30031 or please see our 'contact us' page for further details